PHARMACY

Teva Canada generic lung therapy approved by Health Canada

BY Michael Johnsen

TORONTO — Teva Canada, a subsidiary of Teva Pharmaceutical Industries, announced Tuesday that Health Canada has approved its application for the generic version of PrTarceva. Teva Canada will be the sole generic supplier of this treatment in Canada.
 
PrTeva-Erlotinib is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen, as well as monotherapy for maintenance treatment in patients with stable disease after four cycles of standard first-line chemotherapy.  PrTeva-Erlotinib is also indicated as monotherapy for the first-line treatment of patients with locally advanced (stage III b, not amenable to curative therapy) or metastatic (stage IV) NSCLC with EGFR activating mutations.
 
PrTarceva had annual sales of approximately $15 million in Canada, based on IMS Brogan sales data as of September 2014. PrTeva-Erlotinib is available immediately in pharmacies across Canada.
 
“With today’s announcement, Teva Canada’s industry-leading oncology portfolio, containing 23 drug products, is helping to mitigate the rising costs of cancer treatment in Canada,” stated Doug Sommerville, SVP and general manager of Teva Canada. “Adding PrTeva-Erlotinib to our ever-expanding portfolio of oncology products demonstrates our ongoing commitment to playing a critical role in the sustainability of the healthcare system.”
 
Lung cancer is the most commonly diagnosed cancer in Canada, and the Canadian Cancer Society estimates that in 2014 there will be 26,100 new cases diagnosed, representing 14% of all new cancer cases this year. The most common malignant tumour found in the lung is non-small cell lung cancer, accounting for 85% to 90% of all lung cancers.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

MTM provider Mirixa partners with PioneerRx on patient adherence solution

BY Michael Johnsen

RESTON, Va. — Mirixa Corp., a provider of medication therapy management services, on Tuesday announced a partnership with pharmacy system PioneerRx on a dynamic patient adherence solution. Pharmacists can now view Mirixa patient care opportunities in the PioneerRx pharmacy software, recieve notifications during the dispensing workflow process and link directly to a patient case in the MirixaPro platform using a single sign-on with PioneerRx. 
 
"This integration again demonstrates our commitment to ensure the timely delivery of effective patient care services," said Marvin Richardson, Mirixa CEO. "We are dedicated to our network of pharmacies and continue to look for ways to advance their ability to provide such vital services."
 
"PioneerRx is committed to innovation and focused on helping independent pharmacies succeed," commented Jeff Key, managing director of PioneerRx. "By partnering with Mirixa and baking this cutting-edge functionality directly into the pharmacy workflow, we've created an efficient process that better enables our pharmacies to easily manage a patient's medication adherence and overall health."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Press ECS to exit
Zoom
NC Gov. Pat McCrory gestures as he offers his remarks following the announcement of Eshelman's $100 million commitment to the Eshelman School of Pharmacy at the University of North Carolina.
Dr. Fred Eshelman, left, shakes hands with NC Gov. Pat McCrory following the announcement of Eshelman's $100 million commitment to the Eshelman School of Pharmacy at the University of North Carolina.
Dr. Fred Eshelman, left, shakes hands with Eshelman School of Pharmacy Dean Robert Blouin following the announcement of Eshelman's commitment of $100 million to the school at the University of North Carolina at Chapel Hill Wednesday (Dec. 3).
Dr. Fred Eshelman speaks during a ceremony at the University of North Carolina at Chapel Hill during which his commitment of $100 million to the Eshelman School of Pharmacy was announced. At left is Dr. Robert A. Blouin, dean of the Eshelman School of Pharmacy.
Dr. Fred Eshelman, delivers his remarks following the announcement of Eshelman's commitment of $100 million to the school at the University of North Carolina at Chapel Hill Wednesday (Dec. 3).
Dr. Fred Eshelman, delivers his remarks following the announcement of Eshelman's commitment of $100 million to the school at the University of North Carolina at Chapel Hill Wednesday (Dec. 3).
Dr. Fred Eshelman, left, is applauded by Eshelman School of Pharmacy Dean Robert Blouin following the announcement of Eshelman's commitment of $100 million to the school at the University of North Carolina at Chapel Hill Wednesday (Dec. 3).
Dr. Fred Eshelman, center, is applauded by Chancellor Carol L. Folt, left, and Eshelman School of Pharmacy Dean Robert Blouin, right, following the announcement of his commitment of $100 million to the school at the University of North Carolina at Chapel Hill.
Chancellor Carol L. Folt, center, leads the platform party and the audience in a "Go Heels!" cheer after a ceremony announcing Dr. Fred Eshelman's $100 million commitment to the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill Wednesday (Dec. 3). From left are, Dr. Fred Eshelmann, Dean Robert A. Blouin, Folt, UNC President Tom Ross and NC. Gov. Pat McCrory
From left, Dean Robert A. Blouin, Chancellor Carol L. Folt, Dr. Fred Eshelman, UNC President Tom Ross, NC Gov. Pat McCrory and Vice Chancellor for Development David Routh celebrate Eshelman's $100 million commitment to the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill Wednesday as they prepare to cut a cake in the image of the Old Well following the formal ceremony.
From left, Dean Robert A. Blouin, Chancellor Carol L. Folt, Dr. Fred Eshelman, UNC President Tom Ross, and NC Gov. Pat McCrory celebrate Eshelman's $100 million commitment to the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill Wednesday as they prepare to cut a cake in the image of the Old Well following the formal ceremony.
From left, David Routh, vice chancellor for Development, Chancellor Carol L. Folt, Dr. Fred Eshelman, and Dr. Robert A. Blouin, sign papers accepting Eshelman's $100 million commitment to the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill Wednesday (Dec. 3).
From left, David Routh, vice chancellor for Development, Chancellor Carol L. Folt, Dr. Fred Eshelman, and Dr. Robert A. Blouin, sign papers accepting Eshelman's $100 million commitment to the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill Wednesday (Dec. 3).
From left, David Routh, vice chancellor for Development, Chancellor Carol L. Folt, Dr. Fred Eshelman, and Dr. Robert A. Blouin, enjoy a light moment after signing papers accepting Eshelman's $100 million commitment to the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill Wednesday (Dec. 3).
PHARMACY

UNC-Chapel Hill Eshelman School of Pharmacy receives record donation

BY DSN STAFF

Photos by Dan Sears, the University of North Carolina at Chapel Hill

CHAPEL HILL, N.C. — The University of North Carolina at Chapel Hill last week received a $100 million commitment to the UNC Eshelman School of Pharmacy from alumni Fred Eshelman, founder and CEO of Pharmaceutical Product Development and founding chairman of Furiex Pharmaceuticals.
The donation is the largest from an individual in the university’s history and the largest that’s ever been donated to a pharmacy school in the United States. It will be used to create a center within the pharmacy school named the Eshelman Institute for Innovation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES